Ocugen GAAP EPS of -$0.09 misses by $0.10

May 06, 2022 6:36 AM ETOcugen, Inc. (OCGN)By: Niloofer Shaikh, SA News Editor
  • Ocugen press release (NASDAQ:OCGN): Q1 GAAP EPS of -$0.09 misses by $0.10.
  • OCU400 Phase 1/2 clinical trial for groundbreaking modifier gene therapy for the treatment of NR2E3 and RHO-related retinitis pigmentosa is advancing after DSMB review.

Recommended For You


To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.